Biogen's Alzheimer's drug loses subsidies in the US

The US government is limiting its coverage of Biogen's Alzheimer's drug, Aduhelm, due to the risk of adverse effects. Biogen's stock plummets.

Photo: Pool New/Reuters/Ritzau Scanpix

The US government will cut the subsidies available for Biogen's controversial Alzheimer's drug, Aduhelm, and the decision is being felt on the US stock post-market on Tuesday, reports Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs